<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01534975</url>
  </required_header>
  <id_info>
    <org_study_id>Visipaque</org_study_id>
    <nct_id>NCT01534975</nct_id>
  </id_info>
  <brief_title>Comparison of Contrast Agents During CT Angiography</brief_title>
  <acronym>Visipaque</acronym>
  <official_title>A Prospective, Single-Center Double-Blind Randomized Study in Subjects Undergoing Coronary Computed Tomography Angiography (CCTA) Examination (VISIPAQUE Randomized Study)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Los Angeles Biomedical Research Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>General Electric</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Los Angeles Biomedical Research Institute</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare the effects of a certain contrast agent (iodixanol)
      to two other commonly used contrast agents called Iopamidol (Isovue) and iohexol (Omnipaque),
      on heart and kidney safety in patients undergoing a cardiac CT angiogram. The investigators
      will evaluate whether iodixanol 320 (Visipaque®), an iso-osmolar agent, is better tolerated
      (flushing, injection site pain/warmth, headache, nausea) and provides equal image quality
      compared with iohexol 350 (Omnipaque®) and Isovue 370 during 64-slice multidetector computed
      tomography angiography (MDCTA). A fourth group (Visipaque 270) will be included, using low
      radiation dose technology during acquisition, to evaluate image quality, tolerability, and
      contrast enhancement compared to both Visipaque 320 and Omnipaque and Isovue. In addition to
      image quality, tolerability, and contrast enhancement, the investigators will evaluate heart
      rate, adverse events, reimaging, costs, and patient satisfaction among all four cohorts.

      The study will recruit 400 participants already undergoing CT angiography and consent and
      randomize them to one of four groups. Each of the possible contrast agents used are commonly
      used for CT angiography, so the primary risk is loss of confidentiality and being asked
      questions about tolerability. All other facets of the study (3 lead ECG, beta blockade,
      nitroglycerine use, CT angiography and contrast administration) are standard of care and
      being done for clinical uses.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      CTA infusion is administered using a 5 ml/sec IV iodinated contrast infusion. 50-70 ml of
      iodinated contrast is used for the scan depending on the patient's body habitus. The total
      contrast dose must not exceed 70 ml. An automated bolus tracking feature (SmartPrep, GE
      Healthcare, Milwaukee, USA) is used to judge contrast bolus arrival and optimize image
      quality. Patients will be asked to hold their breaths during scanning for up to 10 seconds. A
      Field of View (FOV) of 25 cm is adjusted to include the heart from below the carina to just
      below diaphragm. The aorta will be included in the FOV to exclude aortic pathology (ie.
      dissection, aneurysm, etc.). For patients in sinus rhythm, prospective ECG gating centered at
      75% of the R-R interval is used while those in Atrial fibrillation or HR &gt;65 despite oral and
      IV medications, a retrospective gating is used. The following parameters are used Tube
      voltage = 100-120kV (based on body habitus), tube current = 400 mA, gantry rotation speed =
      0.35 seconds, slice thickness = 0.625 mm, rows = 64, coverage = 128-160 mm.

      Estimated radiation dose is = 2-5 mSv dependent on BMI, cardiac height and heart rate. A post
      acquisition software (Adaptive Statistical Iterative Reconstruction, GE healthcare,
      Milwaukee, USA) is used to reduce pixel noise standard deviation (noise) by 30 percent and
      allows for reduced mA in the acquisition while still yielding diagnostic images, thereby
      reducing total dose required. At the conclusion of each acquisition, technologists collect a
      survey of patient satisfaction quantifying side effects of different contrasts: flushing,
      headache, nausea, and pain at injection site as mild, moderate or severe.

      Advantage Workstation 4.6 software (GE healthcare, Milwaukee, USA) is used for post
      acquisition processing. Readers, who are blinded to the type of contrast media used, assess
      image quality by measuring contrast enhancement in aorta, LV myocardium, left main, proximal
      Left Anterior Descending artery, proximal and distal Right Coronary arteries. Subjects with
      coronary artery bypass graft and stents are excluded. Heart rate (HR) variability during the
      scan is also evaluated. A comparison of the degree of contrast enhancement of the coronary
      lumen as well as the differences for each of the four contrast agents will be measured and
      reported, stratified by 100 kVp and 120 kVp acquisition. The image quality of 17 coronary
      artery segments will be graded by two cardiologists in consensus with the use of a four-point
      scale (1= excellent, 2=good, 3=fair , 4= poor enhancement) blinded to contrast agent
      administration.

      Statistical Analysis:

      All analysis is conducted using SPSS 18.0 for window (SPSS Inc., Chicago, IL, USA).
      Comparisons between groups are performed using a Student t-test for continuous variables with
      normal distributions and the Mann-Whitney U test for continuous variables with non-normal
      distributions. Categorical variables were analyzed by means of χ2 analysis. Correlation
      between minimum HR and maximum HR was calculated with the Pearson correlation coefficient.
      The Cochran-Mantel-Haenszel test was used for analyzing the difference in visual quality
      between two groups.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2012</start_date>
  <completion_date type="Actual">January 2013</completion_date>
  <primary_completion_date type="Actual">January 2013</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>randomized cohort into 4 groups - each group with a different contrast agent (omnipaque, visipaque 280, visipaque 320, isovue)</intervention_model_description>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Image Quality of the CT Scans Using Different Contrast Agents</measure>
    <time_frame>1 year</time_frame>
    <description>Attenuation (HU) in the ascending aorta, standard deviation (SD) of aorta, will be measured,.</description>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">513</enrollment>
  <condition>Contrast Enhancement on Cardiac CT</condition>
  <arm_group>
    <arm_group_label>Iodixanol 320</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>group 1 will receive iodixanol 320 as the contrast agent during CT acquisition. this will reflect the &quot;intervention&quot; of that arm, by testing the diagnostic ability of this contrast agent to perform cardiac CT angiography</description>
  </arm_group>
  <arm_group>
    <arm_group_label>iohexol 350</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>group 2 will receive iohexol 350 as the contrast agent during CT acquisition. this will reflect the &quot;intervention&quot; of that arm, by testing the diagnostic ability of this contrast agent to perform cardiac CT angiography</description>
  </arm_group>
  <arm_group>
    <arm_group_label>iopamidol 370</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>group 3 will receive iopamidol 370 as the contrast agent during CT acquisition. this will reflect the &quot;intervention&quot; of that arm, by testing the diagnostic ability of this contrast agent to perform cardiac CT angiography</description>
  </arm_group>
  <arm_group>
    <arm_group_label>iodixanol 270</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>group 4 will receive iodixanol 270 as the contrast agent during CT acquisition. this will reflect the &quot;intervention&quot; of that arm, by testing the diagnostic ability of this contrast agent to perform cardiac CT angiography</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>contrast agent</intervention_name>
    <description>we are randomizing patients to different contrast agents.</description>
    <arm_group_label>Iodixanol 320</arm_group_label>
    <arm_group_label>iohexol 350</arm_group_label>
    <arm_group_label>iopamidol 370</arm_group_label>
    <arm_group_label>iodixanol 270</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Subjects may be included in the study if they meet all of the following criteria:

          1. The subject is over 18 years old.

          2. Subject scheduled to undergo a contrast-enhanced CCTA examination

          3. The subject has no contra-indication to receiving iodinated contrast administration
             (allergy, renal insufficiency).

          4. The subject has provided signed and dated informed consent

        Exclusion criteria:

        Subjects must be excluded from participating in this study if they meet the following
        criteria:

          1. Subjects have known contra-indication to contrast administration:

               -  Renal insufficiency as defined by GFR &lt; 50

               -  Known contrast allergy

          2. Pregnant or possibly pregnant subjects will be excluded -Women of childbearing
             potential will undergo urine pregnancy test prior to CT scanning.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>100 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Los Angeles Biomedical Research Institute</name>
      <address>
        <city>Torrance</city>
        <state>California</state>
        <zip>90502</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 14, 2012</study_first_submitted>
  <study_first_submitted_qc>February 16, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 17, 2012</study_first_posted>
  <results_first_submitted>March 10, 2017</results_first_submitted>
  <results_first_submitted_qc>January 31, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">March 1, 2018</results_first_posted>
  <last_update_submitted>January 31, 2018</last_update_submitted>
  <last_update_submitted_qc>January 31, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 1, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>cardiac CT</keyword>
  <keyword>enhancement</keyword>
  <keyword>contrast</keyword>
  <keyword>safety</keyword>
  <keyword>image quality</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Iodixanol 320</title>
          <description>group 1 Iodixanol 320</description>
        </group>
        <group group_id="P2">
          <title>Iohexol 350</title>
          <description>group 2 iohexol 350</description>
        </group>
        <group group_id="P3">
          <title>Iopamidol 370</title>
          <description>group 3 iopamidol 370</description>
        </group>
        <group group_id="P4">
          <title>Iodixanol 270</title>
          <description>group 4 iodixanol 270</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="136"/>
                <participants group_id="P2" count="133"/>
                <participants group_id="P3" count="160"/>
                <participants group_id="P4" count="84"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="136"/>
                <participants group_id="P2" count="133"/>
                <participants group_id="P3" count="160"/>
                <participants group_id="P4" count="84"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Iodixanol 320</title>
          <description>group 1 will receive iodixanol 320 as the contrast agent during CT acquisition. this will reflect the &quot;intervention&quot; of that arm, by testing the diagnostic ability of this contrast agent to perform cardiac CT angiography</description>
        </group>
        <group group_id="B2">
          <title>Iohexol 350</title>
          <description>group 2 will receive iohexol 350 as the contrast agent during CT acquisition. this will reflect the &quot;intervention&quot; of that arm, by testing the diagnostic ability of this contrast agent to perform cardiac CT angiography</description>
        </group>
        <group group_id="B3">
          <title>Iopamidol 370</title>
          <description>group 3 will receive iopamidol 370 as the contrast agent during CT acquisition. this will reflect the &quot;intervention&quot; of that arm, by testing the diagnostic ability of this contrast agent to perform cardiac CT angiography</description>
        </group>
        <group group_id="B4">
          <title>Iodixanol 270</title>
          <description>group 4 will receive iodixanol 270 as the contrast agent during CT acquisition. this will reflect the &quot;intervention&quot; of that arm, by testing the diagnostic ability of this contrast agent to perform cardiac CT angiography</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="136"/>
            <count group_id="B2" value="133"/>
            <count group_id="B3" value="160"/>
            <count group_id="B4" value="84"/>
            <count group_id="B5" value="513"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="92"/>
                    <measurement group_id="B2" value="90"/>
                    <measurement group_id="B3" value="110"/>
                    <measurement group_id="B4" value="60"/>
                    <measurement group_id="B5" value="352"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="44"/>
                    <measurement group_id="B2" value="43"/>
                    <measurement group_id="B3" value="50"/>
                    <measurement group_id="B4" value="24"/>
                    <measurement group_id="B5" value="161"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="62" spread="11.7"/>
                    <measurement group_id="B2" value="62.3" spread="11.4"/>
                    <measurement group_id="B3" value="61.4" spread="10.8"/>
                    <measurement group_id="B4" value="60.4" spread="11.2"/>
                    <measurement group_id="B5" value="62" spread="11.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="66"/>
                    <measurement group_id="B2" value="63"/>
                    <measurement group_id="B3" value="76"/>
                    <measurement group_id="B4" value="40"/>
                    <measurement group_id="B5" value="245"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="70"/>
                    <measurement group_id="B2" value="70"/>
                    <measurement group_id="B3" value="84"/>
                    <measurement group_id="B4" value="44"/>
                    <measurement group_id="B5" value="268"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="136"/>
                    <measurement group_id="B2" value="133"/>
                    <measurement group_id="B3" value="160"/>
                    <measurement group_id="B4" value="84"/>
                    <measurement group_id="B5" value="513"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Image Quality of the CT Scans Using Different Contrast Agents</title>
        <description>Attenuation (HU) in the ascending aorta, standard deviation (SD) of aorta, will be measured,.</description>
        <time_frame>1 year</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Iodixanol 320</title>
            <description>group 1</description>
          </group>
          <group group_id="O2">
            <title>Iohexol 350</title>
            <description>group 2</description>
          </group>
          <group group_id="O3">
            <title>Iopamidol 370</title>
            <description>group 3</description>
          </group>
          <group group_id="O4">
            <title>Iodixanol 270</title>
            <description>group 4</description>
          </group>
        </group_list>
        <measure>
          <title>Image Quality of the CT Scans Using Different Contrast Agents</title>
          <description>Attenuation (HU) in the ascending aorta, standard deviation (SD) of aorta, will be measured,.</description>
          <units>hounsfield units</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="136"/>
                <count group_id="O2" value="133"/>
                <count group_id="O3" value="160"/>
                <count group_id="O4" value="84"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="333" spread="59"/>
                    <measurement group_id="O2" value="357" spread="64"/>
                    <measurement group_id="O3" value="362" spread="68"/>
                    <measurement group_id="O4" value="288" spread="61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Iodixanol 320</title>
          <description>group 1 iodixanol 320</description>
        </group>
        <group group_id="E2">
          <title>Iohexol 350</title>
          <description>group 2 iohexol 350</description>
        </group>
        <group group_id="E3">
          <title>Iopamidol 370</title>
          <description>group 3 iopamidol 370</description>
        </group>
        <group group_id="E4">
          <title>Iodixanol 270</title>
          <description>group 4 iodixanol 270</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="136"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="133"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="84"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>1</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="98" subjects_at_risk="136"/>
                <counts group_id="E2" subjects_affected="122" subjects_at_risk="133"/>
                <counts group_id="E3" subjects_affected="152" subjects_at_risk="160"/>
                <counts group_id="E4" subjects_affected="52" subjects_at_risk="84"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>flushing</sub_title>
                <description>patients reported flushing after administration of contrast</description>
                <counts group_id="E1" events="98" subjects_affected="98" subjects_at_risk="136"/>
                <counts group_id="E2" events="122" subjects_affected="122" subjects_at_risk="133"/>
                <counts group_id="E3" events="152" subjects_affected="152" subjects_at_risk="160"/>
                <counts group_id="E4" events="52" subjects_affected="52" subjects_at_risk="84"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>study was performed as outlined, sample sizes are appropriate, there were no technical problems.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Matthew Budoff</name_or_title>
      <organization>Los Angeles Biomedical Research Institute</organization>
      <phone>3102224107 ext 310</phone>
      <email>mbudoff@labiomed.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

